We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaborat... Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. Show more
REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverumβs Board of...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar...
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.71 | -9.72602739726 | 7.3 | 7.6889 | 6.59 | 261184 | 7.16372178 | CS |
4 | -0.58 | -8.08926080893 | 7.17 | 7.6889 | 6.54 | 168033 | 7.06363797 | CS |
12 | -0.26 | -3.79562043796 | 6.85 | 10.14 | 6.39 | 274484 | 7.74746555 | CS |
26 | -9.16 | -58.1587301587 | 15.75 | 16.435 | 6.38 | 291762 | 8.69266262 | CS |
52 | -9.51 | -59.0683229814 | 16.1 | 29.8 | 6.38 | 749349 | 15.66702263 | CS |
156 | -16.01 | -70.8407079646 | 22.6 | 29.8 | 5.31 | 841950 | 15.1142604 | CS |
260 | -48.91 | -88.1261261261 | 55.5 | 269.8 | 5.31 | 1093853 | 56.68312575 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions